Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Cystic Fibrosis (Nov 2020)

Posted by Matt Breese on Nov 13, 2020

Find me on:

According to our recent payer coverage analysis for cystic fibrosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for cystic fibrosis treatments shows that under the pharmacy benefit, almost 62% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Cystic Fibrosis-4Q2020Data snapshot as of Q4 2020

Trends: In September 2020, the FDA expanded the label of Vertex Pharmaceuticals Inc.'s Kalydeco (ivacaftor) for use in children ages 4 months to less than 6 months old with cystic fibrosis who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to Kalydeco based on clinical and/or in vitro assay data.  

To read the full Reality Check on Cystic Fibrosis treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing